Respected ‘Silicon Review’ lists Co-Diagnostics in 50 Fastest Growing Companies of 2019
July 08 2019 - 7:00AM
Respected ‘Silicon Review’ lists Co-Diagnostics in 50
Fastest Growing Companies of 2019
New York City, New York – The
Silicon Review’s 50 Fastest Growing Companies of the Year for 2019
features Co-Diagnostics, Inc. (Nasdaq: CODX), a
molecular diagnostics company with a unique, patented platform for
the development of molecular diagnostic tests. The July publication
includes highlights of Co-Diagnostics’ history, approach to the
growing diagnostics (and particularly the polymerase chain
reaction, or PCR) sector, and emphasis on quality.
In explaining that the company’s purpose of
existence is first and foremost in its motivations, Co-Diagnostics
CEO Mr. Dwight Egan also describes the company’s approach to
achieving success in part as follows:
“Take what you know you can do, focus on
it, and make it work. Anyone can see a need and create a company to
address it, but maintaining focus on your key revenue drivers long
enough to make meaningful revenue is where so many other companies
fall short.”
Release of the interview follows recent news by Co-Diagnostics
that their highly specific multiplex test for Zika, dengue, and
chikungunya was enthusiastically received at CARPHA 2019, and that
domestic sales of their mosquito vector control products have
commenced. Analysts from H.C. Wainwright and Maxim Group recently
set a price target of $2.00 for CODX.
The Silicon Review is the pre-eminent platform
for sharing innovative enterprise solutions developed by
established solution providers and upcoming hot enterprises.
Emphasizing as a neutral source for decision makers, the
publication acts as an excellent medium, allowing top level
executives to share their contemporary thoughts and ideas. The
feature can be found here: https://bit.ly/2Nv4aC7
About BDA International,
Inc.:
BDA International is an independent global
Investor Relations firm offering a wide range of IR-related
analysis, research and advisory services. In particular, we provide
and are compensated for service packages that include strategic
action plans and investor/market perception studies to help
entities improve communication with customers and investors, and to
increase their visibility. BDA International has received no direct
compensation related to this release but its principles may also in
some circumstances hold some of shares of client companies in our
personal portfolios, including CODX. BDA International accepts sole
responsibility for the content and distribution of the foregoing
release, which does not contain any previously unpublished or
non-public information. Parties interested in learning more about
the relationship between BDA and CODX may do so via the contact
information at the bottom of this release.
Disclaimer
The information, opinions and analysis
contained herein are based on sources believed to be reliable, but
no representation, expressed or implied, is made as to its
accuracy, completeness or correctness. The opinions contained in
this analysis reflect our current judgment and are subject to
change without notice. We do not accept any responsibility or
liability for any losses, damages or costs arising from an
investor’s or other person’s reliance on or use of this analysis.
This analysis is for information purposes only, and is neither a
solicitation to buy nor an offer to sell securities, nor a
recommendation of any security, although members of the BDA may at
times hold a position in the company covered within the article.
Co-Diagnostics is a client of BDA International. Past gains are not
a representative of future gains. The opinions herein contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, statements concerning manufacturing, marketing, growth,
and expansion. When used herein, the words “anticipate,” “intend,”
“estimate,” “believe,” “expect,” “plans,” “should,” “potential,”
“forecast,” and variations of such words and similar expressions
are intended to identify forward-looking statements. Such
forward-looking information involves important risks and
uncertainties that could affect actual results and cause them to
differ materially from expectations expressed herein. A company’s
actual results could differ materially from those described in any
forward-looking statements contained herein. BDA is not a licensed
broker, broker dealer, market maker, investment advisor, analyst or
underwriter. We recommend that you use the information found herein
as an initial starting point for conducting your own research in
order to determine your own personal opinion of the companies
discussed herein before deciding whether or not to invest. You
should seek such investment, tax, financial, accounting or legal
advice appropriate for your particular circumstances. Information
about many publicly traded companies and other investor resources
can be found at www.sec.gov. Investing in securities is speculative
and carries risk.
Investor Relations
Contact:
BDA International www.bda-ir.com
dost@bda-ir.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2023 to Apr 2024